- Datum15.01.2025
- Uhrzeit15:00 - 15:30 Uhr
- Veranstalter
stock3
Thomas May
Moderator
Syndax Pharmaceuticals Inc. Aktie
Verkaufen
Kaufen
Syndax Pharmaceuticals Inc. Chart
stock3 TerminalDu willst selbst ins Charting einsteigen?
Nutze das Charting-Widget auf dem stock3 Terminal für Deine eigene Analyse. Mehr Features. Mehr Werkzeuge. Mehr stock3.
Chart im Terminal öffnen
Syndax Pharmaceuticals Inc. Realtime-Kurs
| Name | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate | VK | |||||
| Stuttgart | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
1,79 %
Intraday
-6,10 %
1 Woche
-18,71 %
1 Monat
-39,47 %
Seit Jahresbeginn
-37,54 %
1 Jahr
-39,75 %
3 Jahre
63,50 %
5 Jahre
Wikifolio
Passender Service zu Syndax Pharmaceuticals Inc.
Webinar zu Syndax Pharmaceuticals Inc.
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)12,750-25,340
- Jahrestief / Hoch ($)12,750-25,340
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Syndax Pharmaceuticals Inc.
Keine Dividenden verfügbar
Termine von Syndax Pharmaceuticals Inc.
- Mär5Syndax Pharmaceuticals Inc.Q4 2024 Earnings Release
- Mai12Syndax Pharmaceuticals Inc.Q1 2025 Earnings Release
- Aug11Syndax Pharmaceuticals Inc.Q2 2025 Earnings Release
Beschreibung
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.
